Literature DB >> 12093359

Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions.

Urs A Boelsterli1.   

Abstract

Some carboxylic acid-containing drugs have been implicated in rare but serious adverse reactions. These compounds can be bioactivated via two distinct pathways: by UDP-glucuronosyltransferase-catalyzed conjugation with glucuronic acid, resulting in the formation of acyl glucuronides, or by acyl-CoA synthetase-catalyzed formation of acyl-CoA thioesters. This review compares the two types of potentially reactive metabolites with respect to their stability, protein-reactivity, target selectivity, and disposition in the liver, and summarizes the evidence which links acyl glucuronide and acyl-CoA thioester formation with downstream toxicologic effects. While with increasing drug concentration the acyl glucuronide pathway may prevail, CoA intermediates may be more reactive. Both metabolites are electrophilic species which can acylate target proteins if they escape inactivation by S-glutathione-thioester formation. A crucial factor is the up-concentration of acyl glucuronides in hepatocytes and the biliary tree, due to vectorial transport by conjugate export pumps, where they may selectively acylate canalicular membrane proteins. Furthermore, positional isomers, which are avidly formed by acyl migration, can glycate proteins in the liver and at more distal sites. In contrast, acyl-CoA esters may be more rapidly hydrolysed or further metabolized in hepatocytes, and their hepatobiliary transport has not been well explored. While there is accumulating evidence that acyl glucuronides can alter cellular function by various mechanisms, including haptenation of peptides, critical protein acylation or glycation, or direct stimulation of neutrophils and macrophages, the role of acyl-CoA intermediates is less clear. More work is needed to provide a causal link between protein-reactive acyl glucuronides and acyl-CoA thioesters and the rare and unpredictable idiosyncratic drug reactions in humans.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12093359     DOI: 10.2174/1389200023337315

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  18 in total

1.  Silver oxide nanoparticles alleviate indomethacin-induced gastric injury: a novel antiulcer agent.

Authors:  Neveen A Salem; Mohammed A Wahba; Wael H Eisa; Marwa El-Shamarka; Wagdy Khalil
Journal:  Inflammopharmacology       Date:  2017-12-04       Impact factor: 4.473

2.  Expression of drug metabolizing enzymes and transporters in the cochlea: Implications for drug delivery and ototoxicity.

Authors:  Stefanie Kennon-McGill; Melissa M Clemens; Mitchell R McGill
Journal:  Hear Res       Date:  2019-05-15       Impact factor: 3.208

3.  Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs).

Authors:  Jin Zhou; Upendra A Argikar; John O Miners
Journal:  Methods Mol Biol       Date:  2021

4.  The Application of Mass Spectrometry in Drug Metabolism and Pharmacokinetics.

Authors:  Ji-Yoon Lee; Sang Kyum Kim; Kiho Lee; Soo Jin Oh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  Managing the challenge of chemically reactive metabolites in drug development.

Authors:  B Kevin Park; Alan Boobis; Stephen Clarke; Chris E P Goldring; David Jones; J Gerry Kenna; Craig Lambert; Hugh G Laverty; Dean J Naisbitt; Sidney Nelson; Deborah A Nicoll-Griffith; R Scott Obach; Philip Routledge; Dennis A Smith; Donald J Tweedie; Nico Vermeulen; Dominic P Williams; Ian D Wilson; Thomas A Baillie
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

6.  Glucuronidation and covalent protein binding of benoxaprofen and flunoxaprofen in sandwich-cultured rat and human hepatocytes.

Authors:  Jennifer Q Dong; Philip C Smith
Journal:  Drug Metab Dispos       Date:  2009-09-22       Impact factor: 3.922

7.  Stereoselective flunoxaprofen-S-acyl-glutathione thioester formation mediated by acyl-CoA formation in rat hepatocytes.

Authors:  Mark P Grillo; Jill C M Wait; Michelle Tadano Lohr; Smriti Khera; Leslie Z Benet
Journal:  Drug Metab Dispos       Date:  2010-01       Impact factor: 3.922

8.  LC-ESI-MS/MS reveals the formation of reactive intermediates in brigatinib metabolism: elucidation of bioactivation pathways.

Authors:  Adnan A Kadi; Mohamed W Attwa; Hany W Darwish
Journal:  RSC Adv       Date:  2018-01-03       Impact factor: 3.361

9.  A novel aromatic carboxylic acid inactivates luciferase by acylation of an enzymatically active regulatory lysine residue.

Authors:  Madoka Nakagomi; Nobuko Fujimaki; Ai Ito; Takahiro Toda; Hiroshi Fukasawa; Koichi Shudo; Ryoichi Tomita
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

Review 10.  The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity.

Authors:  Volker M Lauschke; Magnus Ingelman-Sundberg
Journal:  Int J Mol Sci       Date:  2016-10-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.